DIVIS LAB

surged 4% to touch a day’s high of Rs 6,764.00 on 26th May after the company announced that it had inked a long-term manufacturing and supply agreement with a global pharmaceutical company. Under the deal, Divi’s will manufacture and supply advanced intermediates, with commercial terms agreed by both parties. The unnamed customer expects significant revenue contribution from this long-term agreement. Capacity expansion under the deal will cost Rs 650–750 crore, funded by phase-wise advances from the customer.